4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ™” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging.
Please select your region to see the most relevant content and products available in your area.
You are navigating to content specific to another region. Do you wish to proceed?
Availability varies by region. Refer to product labelling for intended use.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.